Limited Edition Golden Llama is here! Check out how you can get one. 
Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Offering SPR-BLI Services - Proteins provided for free!
Here come GMP Grade Cytokines！Free Sample is available！ Here come GMP Grade Cytokines！Free Sample is available！
GMP Human IL-2 Protein (Cat. No. GMP-L02H14) stimulates proliferation of CTLL-2 cells. The specific activity of GMP Human IL-2 Protein is ≥ 1.20×10^7 IU/mg, which is calibrated against human Interleukin-2 China National Standard (NIFDC code: 270008) (QC tested). China National Institutes for Food and Drug Control (NIFDC) Standard was prepared and calibrated against human IL-2 WHO International Standard (NIBSC code: 86/500) by NIFDC.
Human IL-2 Protein, Tag Free (Cat. No. IL2-H5215) stimulates proliferation of CTLL-2 cells. The specific activity of Human IL-2 Protein, Tag Free is > 5.00×10^6 IU/mg, which is calibrated against Interleukin-2 (Human, rDNA derived) (2nd International Standard) (NIBSC code: 86/500) (QC tested).
Cynomolgus IL-2 R beta, His Tag (Cat. No. ILB-C52H9) immobilized on CM5 Chip can bind Cynomolgus IL-2, His Tag (Cat. No. IL2-C5249) with an affinity constant of 377 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Thalidomide | NSC-66847; NSC-527179; K-17; VP-02 | Approved | Celgene Corp | Talizer, Thalidomide Celgene, Thalidomide Pharmion, Synovir, Thalomid, Thaled | Japan | Leprosy, Lepromatous | Fujimoto Pharmaceutical | 1982-01-01 | Osteosarcoma; Leprosy, Lepromatous; Drug Resistant Epilepsy; Primary Myelofibrosis; Neuroectodermal Tumors, Primitive; Prostatitis; Colorectal Neoplasms; Lymphoma, Mantle-Cell; Sarcoma, Ewing; Retinoblastoma; Waldenstrom Macroglobulinemia; Cholangitis, Sclerosing; HIV Wasting Syndrome; Arachnoiditis; Adenocarcinoma, Clear Cell; Prostatic Neoplasms; Pancreatitis, Chronic; Lymphoma, Follicular; Sarcoma; Xerostomia; Burning Mouth Syndrome; Neoplasm Metastasis; Mycobacterium avium-intracellulare Infection; Vascular Malformations; Amyotrophic Lateral Sclerosis; Melanoma; Carcinoma, Hepatocellular; Leukemia, Lymphocytic, Chronic, B-Cell; Myelodysplastic-Myeloproliferative Diseases; Stomatitis; Erythema Nodosum; Anemia, Sideroblastic; Uterine Neoplasms; Lymphoma, Non-Hodgkin; Glioma; Angiodysplasia; Pelvic Pain; Appendiceal Neoplasms; Lung Neoplasms; Endometrial Neoplasms; Mycobacterium Infections; Gastric Antral Vascular Ectasia; Carcinoid Tumor; Lupus Erythematosus, Discoid; Stomatitis, Aphthous; Rhabdomyosarcoma; | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| T20K | T-20K | Phase 1 Clinical | Cyxone | Multiple Sclerosis | Details |
| RG-6279 | RG-6279 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Solid tumours | Details |
| S-95007 | S-95007 | Phase 2 Clinical | Laboratoires Servier | Immune System Diseases; Inflammation | Details |
| SAR-444336 | SAR-444336 | Phase 1 Clinical | Sanofi | Inflammation | Details |
| LMBP2-specific TCR-T cell therapy (TCRCure Biopharma) | Phase 2 Clinical | Tcrcure Biopharma Ltd | Nasopharyngeal Carcinoma | Details | |
| SHR-1916 | SHR-1916 | Phase 1 Clinical | Jiangsu Hengrui Medicine Co Ltd | Solid tumours | Details |
| STK-012 | STK-012 | Phase 1 Clinical | Synthekine Inc | Solid tumours; Ovarian Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Transitional Cell; Microsatellite instability-high cancer; Melanoma; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| Darleukin/fibromun | L19-IL-2/ L19-TNF-α | Phase 3 Clinical | Philogen Spa | Carcinoma, Merkel Cell; Carcinoma, Skin Appendage; Basal Cell Nevus Syndrome; Keratoacanthoma; Carcinoma, Squamous Cell; Lymphoma, T-Cell, Cutaneous; Melanoma; Sarcoma, Kaposi | Details |
| ITI-1000 | ITI-1000 | Phase 2 Clinical | Immunomic Therapeutics Inc | Glioblastoma | Details |
| NNC-0361-0041 | NNC0361-0041; NNC-0361-0041 | Phase 1 Clinical | Novo Nordisk A/S | Diabetes Mellitus, Type 1 | Details |
| XTX-202 | XTX-202 | Phase 2 Clinical | Solid tumours | Details | |
| Interleukin-2 gene therapy (St Jude Children's Research Hospital) | Phase 1 Clinical | St Jude Children's Research Hospital, National Cancer Institute | Neuroblastoma | Details | |
| AU-007 | BD-8; AU-007; BDG-8 | Phase 2 Clinical | Biolojic Design Inc | Solid tumours; Neoplasms; Neoplasm Metastasis | Details |
| PM-1016 | PM1016; TILT-123 | Phase 2 Clinical | Tilt Biotherapeutics Ltd | Ovarian Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Hepatocellular; Melanoma | Details |
| EQ101 | EQ101 | Phase 2 Clinical | Equillium Inc | Alopecia; Alopecia Areata | Details |
| Bifikafusp alfa | L19-IL-2 | Phase 3 Clinical | Philogen Spa | Solid tumours; Carcinoma, Basal Cell; Lymphoma, Large B-Cell, Diffuse; Carcinoma, Squamous Cell; Melanoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis | Details |
| attIL2-T cell therapy | Phase 1 Clinical | MD Anderson Cancer Center | Soft Tissue Neoplasms; Osteosarcoma; Sarcoma | Details | |
| Saltikva | Phase 2 Clinical | Salspera LLC | Pancreatic Neoplasms | Details | |
| AVB-001 | AVB-001 | Phase 2 Clinical | Avenge Bio Inc | Ovarian Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms | Details |
This web search service is supported by Google Inc.
A-Z
